Literature DB >> 20934897

HbA(1c) in the prediction of type 2 diabetes compared with fasting and 2-h post-challenge plasma glucose: The Asturias study (1998-2005).

S Valdés1, P Botas, E Delgado, F Alvarez, F Díaz-Cadórniga.   

Abstract

AIM: Fasting plasma glucose (FPG) and the 2-h post-challenge plasma glucose (2hPG) are commonly used to identify those at risk of type 2 diabetes. However, the role of HbA(1c) in this prediction has still not been ascertained.
METHODS: The Asturias study is a prospective population-based survey of diabetes and cardiovascular risk factors. Baseline examination, carried out during 1998-1999, involved 1034 individuals, aged 30-75 years, randomly selected to determine the prevalence of type 2 diabetes and prediabetes in the principality of Asturias (northern Spain). In 2004-2005, these same subjects were invited to a follow-up examination, and 700 participated. The present study includes only those who did not have diabetes at baseline. All participants with no known diabetes underwent an OGTT. Baseline HbA(1c) levels were measured by HPLC.
RESULTS: Diabetes had developed in 44 participants at the time of follow-up. Quartiles of baseline HbA(1c) values were 3.4-4.8 (Q1), 4.9-5.1 (Q2), 5.2-5.4 (Q3) and 5.5-6.9 (Q4), and the incidence rates of diabetes by quartiles were 1.0 (0.1-7.1), 4.0 (1.5-10.7), 7.9 (4.0-15.9) and 32.6 (22.9-46.4) cases/1000 person-years, respectively. ROC curve analysis comparing HbA(1c), FPG and 2hPG in the prediction of diabetes showed areas under the curve (ROC-AUC) of 0.80 (0.74-0.86), 0.83 (0.77-0.90) and 0.79 (0.72-0.87), respectively. The combination of FPG and HbA(1c) had the best predictive performance with an ROC-AUC of 0.88 (0.82-0.93).
CONCLUSION: Our study indicates that HbA(1c) is strongly predictive of new-onset diabetes in this northern Spanish population, and was similar to FPG and 2hPG in predictive capability. Also, the combined measurement of FPG and HbA(1c) improved their individual predictive performance.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20934897     DOI: 10.1016/j.diabet.2010.07.002

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  6 in total

1.  Smoking causes the disorder of glucose metabolism under different levels of blood pressure in male occupational population.

Authors:  Dan Wang; Deren Qiang; Wenchao Xu; Jiaqi Wang; Jiali Liu; Yu Qin; Yongqing Zhang; Qizhan Liu; Quanyong Xiang
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-08-09       Impact factor: 2.885

Review 2.  Type 2 Diabetes Prevention: Implications of Hemoglobin A1c Genetics.

Authors:  Aaron Leong; James B Meigs
Journal:  Rev Diabet Stud       Date:  2016-02-10

3.  Elevated HbA1c and fasting plasma glucose in predicting diabetes incidence among older adults: are two better than one?

Authors:  Kasia J Lipska; Silvio E Inzucchi; Peter H Van Ness; Thomas M Gill; Alka Kanaya; Elsa S Strotmeyer; Annemarie Koster; Karen C Johnson; Bret H Goodpaster; Tamara Harris; Nathalie De Rekeneire
Journal:  Diabetes Care       Date:  2013-10-17       Impact factor: 19.112

4.  Prediction of Type 2 Diabetes by Hemoglobin A1c in Two Community-Based Cohorts.

Authors:  Aaron Leong; Natalie Daya; Bianca Porneala; James J Devlin; Dov Shiffman; Michael J McPhaul; Elizabeth Selvin; James B Meigs
Journal:  Diabetes Care       Date:  2017-10-26       Impact factor: 19.112

5.  HbA1c Cutoff Point of 5.9% Better Identifies High Risk of Progression to Diabetes among Chinese Adults: Results from a Retrospective Cohort Study.

Authors:  Kai Liang; Chuan Wang; Fei Yan; Lingshu Wang; Tianyi He; Xiuping Zhang; Chengqiao Li; Weifang Yang; Zeqiang Ma; Aixia Ma; Xinguo Hou; Li Chen
Journal:  J Diabetes Res       Date:  2018-06-13       Impact factor: 4.011

6.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.